*Starting doses must be administered in the deltoid muscle.
Due to the difference in median pharmacokinetic profiles between the 2 products (INVEGA® SUSTENNA® and INVEGA® Oral), caution should be exercised when making a direct comparison of their pharmacokinetic properties.
For patients who have never taken oral paliperidone or oral or injectable risperidone, it is recommended to establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA® SUSTENNA®.1
NOTE: Establish tolerability with oral paliperidone or oral risperidone before starting INVEGA® SUSTENNA®. No oral supplementation is needed.
Paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone, risperidone, or to any components of the formulation.
|Missed monthly maintenance dose||Dosing schedule|
|1 month to 6 weeks since last injection||Resume regular monthly dosing as soon as possible at patient’s previously stabilized dose.|
|>6 weeks to 6 months since last injection
*If the patient was stabilized on 234 mg, the first 2 doses should be 156 mg.
|Continue dosing at patient’s previously stabilized dose* by giving:
|>6 months since last injection||Restart dosing with normal starting plan:
|Missed second starting dose||Dosing schedule|
|<4 weeks from first injection||
Administer the second starting dose of 156 mg in the deltoid muscle as soon as possible.
It is recommended to administer a third injection of 117 mg 5 weeks after the first injection (regardless of the timing of the second injection).
Regular monthly dosing in either the deltoid or gluteal muscle should be followed thereafter.
|4-7 weeks from first injection||Resume dosing with 2 injections of 156 mg:
Regular monthly dosing in either deltoid or gluteal muscle should be followed thereafter.
|>7 weeks from first injection||Restart dosing with normal starting plan:
INVEGA® SUSTENNA® has a proven safety and tolerability profile. Explore the data >
References: 1. INVEGA® SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; April 2014. 2. Data on file. Johnson & Johnson Pharmaceutical Research & Development, LLC. Document ID: EDMS-PSDB-2975118:4.0.